Author:
Mukherjee Manali,Lim Hui Fang,Thomas Sruthi,Miller Douglas,Kjarsgaard Melanie,Tan Bruce,Sehmi Roma,Khalidi Nader,Nair Parameswaran
Publisher
Springer Science and Business Media LLC
Subject
Pulmonary and Respiratory Medicine,Immunology,Immunology and Allergy
Reference16 articles.
1. FDA approves Nucala to treat severe asthma. US Food and Drug Administration: US Department of Health and Human Services; 2015. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm471031.htm . Accessed 10 Sept 2016.
2. Bel E, Wenzel S, Thompson P, Prazma C, Keene O, Yancey S, et al. Oral glucocorticoid-sparing effect of Mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371:1189–97.
3. Nair P, Pizzichini M, Kjarsgaard M. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009;360:985–93.
4. Finkelman FD, Madden KB, Morris SC, Holmes JM, Boiani N, Katona IM, et al. Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes. J Immunol. 1993;151:1235–44.
5. Smith SG, Chen R, Kjarsgaard M, Huang C, Oliveria JP, O’Byrne PM, et al. Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia. J Allergy Clin Immunol. 2016;137(1):75–86.e8.
Cited by
49 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献